Nissui Pharmaceutical Co., Ltd. operates within the Diagnostic substances sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Nissui Pharmaceutical Co., Ltd. with three other
pharmaceutical manufacturers in Asia:
Wai Yuen Tong Medicine Holdings Ltd
of Hong Kong
sales of 825.33 million Hong Kong Dollars [US$106.43 million]
Searle Co Ltd
(11.29 billion Pakistan Rupees [US$107.72 million]
Shilpa Medicare Limited
based in India
(7.19 billion Indian Rupees [US$105.53 million]
of which 88%
was Bulk Drugs).
During the year ended March of 2016, sales at
Nissui Pharmaceutical Co., Ltd. were ¥12.02 billion (US$104.90 million).
a very small
increase of 1.3%
versus 2015, when the company's sales were ¥11.86 billion.
Despite this increase, sales are still
below the level achieved in 2014, when Nissui Pharmaceutical Co., Ltd.
reported sales of ¥13.14 billion.
The sales level in 2016 was fairly close to the level five years ago: in 2011, Nissui Pharmaceutical Co., Ltd. had sales
of ¥13.28 billion.
Sales of Industry Test Drug Business saw an increase
that was more than double the company's growth rate: sales were up
3.3% in 2016, from
¥2.84 billion to ¥2.94 billion.
Nissui Pharmaceutical Co., Ltd. also saw significant increases in sales in
Clinical Diagnostics Business (up 1.8% to ¥5.17 billion)
Cosmetics (up 2.9% to ¥928.15 million)
Not all segments of Nissui Pharmaceutical Co., Ltd. experienced an increase in sales in 2016:
sales of Pharmaceuticals fell 2.0% to ¥2.98 billion.